Healthline3 outlets · 16h ago
FDA Initiates Labeling Changes for GLP-1s Due to Rare But Serious Eye Disease Risk
A rare eye disease has been added to the growing list of side effects linked to GLP-1s, adding a second eye warning to several labels. Michael Siluk/UCG/Universal Images Group via Getty Images The FDA is requiring new warnings on Ozempic, Wegovy, Mounjaro, Zepbound, and other GLP-1s about a potential increase in the…